Genentech takes steps to protect Lucentis
Executive Summary
As of Nov. 30, Genentech will no longer allow compounding pharmacies to purchase its VEGF inhibitor Avastin from authorized wholesale distributors, the firm announces Oct. 11 in a letter to retinal physicians. The move is to prevent the off-label use of Avastin (bevacizumab), which is approved for oncologic uses, for wet age-related macular degeneration in place of Genentech's VEGF inhibitor Lucentis (ranibizumab), which is approved for AMD. Genentech's letter notes that "FDA raised concerns related to the sterility and repackaging of Avastin for ocular use in a warning letter to a compounding pharmacy and, separately, during a routine FDA inspection of our South San Francisco manufacturing facility, concerns were raised ... related to the ongoing ocular use of Avastin because it is not designed, manufactured or approved for this use." The National Eye Institute is running trials studying Avastin in ocular settings, including a head-to-head comparison with Lucentis in AMD (1"The Pink Sheet" April 16, 2007, p. 8)...
You may also be interested in...
Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions
Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups
Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.